Format

Send to

Choose Destination
Sci Data. 2016 Oct 11;3:160089. doi: 10.1038/sdata.2016.89.

Human whole genome genotype and transcriptome data for Alzheimer's and other neurodegenerative diseases.

Author information

1
Mayo Clinic, Department of Neuroscience, 4500 San Pablo Road, Jacksonville, Florida 32224, USA.
2
Institute for Systems Biology, 401 Terry Ave N., Seattle, Washington 98109, USA.
3
Mayo Clinic, Department of Health Sciences Research, 4500 San Pablo Road, Jacksonville, Florida 32224, USA.
4
Mayo Clinic, Department of Health Sciences Research, 200 First Street, Rochester, Minnesota 55905, USA.
5
Sage Bionetworks, 1100 Fairview Ave. N., Seattle, Washington 98109, USA.
6
University of Florida, Center for Translational Research in Neurodegenerative Diseases, 1275 Center Dr, Gainesville, Florida 32611, USA.
7
Mayo Clinic, Department of Neurology, 200 First Street, Rochester, Minnesota 55905, USA.
8
Mayo Clinic, Department of Neurology, 4500 San Pablo Road, Jacksonville, Florida 32224, USA.

Abstract

Previous genome-wide association studies (GWAS), conducted by our group and others, have identified loci that harbor risk variants for neurodegenerative diseases, including Alzheimer's disease (AD). Human disease variants are enriched for polymorphisms that affect gene expression, including some that are known to associate with expression changes in the brain. Postulating that many variants confer risk to neurodegenerative disease via transcriptional regulatory mechanisms, we have analyzed gene expression levels in the brain tissue of subjects with AD and related diseases. Herein, we describe our collective datasets comprised of GWAS data from 2,099 subjects; microarray gene expression data from 773 brain samples, 186 of which also have RNAseq; and an independent cohort of 556 brain samples with RNAseq. We expect that these datasets, which are available to all qualified researchers, will enable investigators to explore and identify transcriptional mechanisms contributing to neurodegenerative diseases.

PMID:
27727239
PMCID:
PMC5058336
DOI:
10.1038/sdata.2016.89
[Indexed for MEDLINE]
Free PMC Article

Conflict of interest statement

Below are the disclosures for R.C.P.: Pfizer, Inc., and Janssen Alzheimer Immunotherapy: Chair, Data Monitoring Committee. Hoffman-La Roche, Inc.: Consultant. Merck, Inc.: Consultant. Genentech, Inc.: Consultant. Biogen, Inc.: Consultant. Eli Lilly & Co.: Consultant. N.R.G.-R. has multicenter treatment study grants from Lilly and TauRx and consulted for Cytox. N.E.-T. has consulted for Cytox. The remaining authors declare no competing financial interests.

Supplemental Content

Full text links

Icon for Nature Publishing Group Icon for PubMed Central
Loading ...
Support Center